Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Share-based Compensation (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of Share-based Compensation data on record, last reported at $1.8 million in Q2 2025.

  • For Q2 2025, Share-based Compensation rose 13.58% year-over-year to $1.8 million; the TTM value through May 2025 reached $10.2 million, up 63.81%, while the annual FY2025 figure was $10.2 million, 63.81% up from the prior year.
  • Share-based Compensation reached $1.8 million in Q2 2025 per LFCR's latest filing, down from $2.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $3.4 million in Q4 2024 and bottomed at $620000.0 in Q3 2021.
  • Average Share-based Compensation over 5 years is $1.3 million, with a median of $1.0 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: crashed 30.49% in 2021, then surged 113.82% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $686000.0 in 2021, then surged by 61.52% to $1.1 million in 2022, then skyrocketed by 42.33% to $1.6 million in 2023, then surged by 113.82% to $3.4 million in 2024, then tumbled by 46.17% to $1.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $1.8 million in Q2 2025, $2.6 million in Q1 2025, and $3.4 million in Q4 2024.